ArticleNature communications2022

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.

Jennifer Cantley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.